Similar articles

• Narcotic antagonists in the treatment of opioid dependence: review and commentary.

  Resnick RB, Schuyten-Resnick E, Washton AM. Resnick RB, et al. Compr Psychiatry. 1979 Mar-Apr;20(2):116-25. doi: 10.1016/0010-440x(79)90042-7. Compr Psychiatry. 1979. PMID: 421447 No abstract available.
• A history of the development of narcotic antagonists for the treatment of narcotic addiction.

  Martin WR. Martin WR. NIDA Res Monogr. 1978;(19):296-300. NIDA Res Monogr. 1978. PMID: 218106 No abstract available.
• The role of the federal government in the development of narcotic antagonists.

  Green AI. Green AI. Adv Biochem Psychopharmacol. 1973;8(0):576-7. Adv Biochem Psychopharmacol. 1973. PMID: 4795123 No abstract available.
• Methadone maintenance and narcotic blocking drugs. Appendix.

  Wikler A. Wikler A. Int J Addict. 1977 Oct;12(7):869-81. doi: 10.3109/10826087709027257. Int J Addict. 1977. PMID: 338517 Review.
• Research on naltrexone in the criminal justice system.

  Patapis NS, Nordstrom BR. Patapis NS, et al. J Subst Abuse Treat. 2006 Sep;31(2):113-5. doi: 10.1016/j.jsat.2006.06.021. Epub 2006 Aug 2. J Subst Abuse Treat. 2006. PMID: 16919735 Review.